US 11,833,166 B2
Pharmaceutical composition, methods for treating and uses thereof
Uli Christian Broedl, Mainz am Rhein (DE); Sreeraj Macha, Basking Ridge, NJ (US); Maximilian von Eynatten, Wiesbaden (DE); and Hans-Juergen Woerle, Grandvaux VD (CH)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Jun. 10, 2021, as Appl. No. 17/344,003.
Application 17/344,003 is a continuation of application No. 16/288,192, filed on Feb. 28, 2019, granted, now 11,090,323.
Application 16/288,192 is a continuation of application No. 15/918,401, filed on Mar. 12, 2018, granted, now 10,258,637, issued on Apr. 16, 2019.
Application 15/918,401 is a continuation of application No. 14/918,727, filed on Oct. 21, 2015, granted, now 9,949,998, issued on Apr. 24, 2018.
Application 14/918,727 is a continuation of application No. 14/244,208, filed on Apr. 3, 2014, abandoned.
Claims priority of provisional application 61/908,991, filed on Nov. 26, 2013.
Claims priority of provisional application 61/808,804, filed on Apr. 5, 2013.
Prior Publication US 2021/0299153 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7034 (2006.01); A61K 31/7048 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01)
CPC A61K 31/7048 (2013.01) [A61K 9/2018 (2013.01); A61K 9/2866 (2013.01); A61K 31/7034 (2013.01)] 24 Claims
 
1. A method for improving glycemic control in a patient with type 2 diabetes mellitus comprising:
a) assessing the renal function of the patient; and
b) administering empagliflozin to the patient if the eGFR of the patient is
≥45 ml/min/1.73 m2 and <60 ml/min/1.73 m2,
wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg, and
wherein the glycemic control in said patient is improved.